000			01178naa a2200169uu 4500
001			6012717591517
003			OSt
005			20190211160629.0
008			060127s2006 xx ||||gr |0|| 0 eng d
100	1		_aKAY, Adrian _95460
245	1	0	_aPharmaceutical Policy in the UK
260			_aOxford : _bBlackwell Publishing, _cOctober - December 2001
520	3		_aFor many years drug price regulation posed few public management problems. However, the overall NHS drugs budget has been increasing by almost 9% per annum over the past decade. Governments in the 1990s tried to control this growth by introducing new pharmaceutical policy instruments. This has led to an element of instability in the regulation of the pharmaceutical industry, which is affecting NHS financial programming, as well as R&D investment decisions by companies. This article recommends the creation of an office for drug regulation (an 'OFDRUG') to reintroduce stability into pharmaceutical policy
773	0	8	_tPublic Money & Management _g21, 4, p. 51-54 _dOxford : Blackwell Publishing, October - December 2001 _xISSN 0954-0962 _w
942			_cS
998			_a20060127 _b1759^b _cAnaluiza
999			_aConvertido do Formato PHL _bPHL2MARC21 1.1 _c14753 _d14753
041			_aeng